Erratum

In the published article titled “Osimertinib in non-small cell lung cancer: real world data from New Zealand,” JTO Clin Res Rep. 2020;1:100022, the authors wish to add the following disclosure statement:

AstraZeneca provided osimertinib to patients as part of a compassionate access program and provided writing support but no direct funding for the review.

Address for correspondence: Laird Cameron, MbCh, FRACP. E-mail: LairdC@adhb.govt.nz